Implantica AG (IMP-A-SDB.ST)
SEK 27.15
(0.56%)
SEK 27.15
(0.56%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 21.93 Million EUR | 6.04% |
| 2022 | 20.68 Million EUR | 48.28% |
| 2021 | 13.94 Million EUR | 62.45% |
| 2020 | 8.58 Million EUR | 150.03% |
| 2019 | 3.43 Million EUR | -33.0% |
| 2018 | 5.12 Million EUR | 32.22% |
| 2017 | 3.87 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 6.06 Million EUR | -17.21% |
| 2024 Q1 | 7.32 Million EUR | -29.15% |
| 2023 Q1 | 5.26 Million EUR | -31.52% |
| 2023 FY | 25.16 Million EUR | 21.69% |
| 2023 Q4 | 10.34 Million EUR | 82.22% |
| 2023 Q3 | 5.67 Million EUR | 46.07% |
| 2023 Q2 | 3.88 Million EUR | -26.22% |
| 2022 Q4 | 7.68 Million EUR | 72.5% |
| 2022 Q3 | 4.45 Million EUR | 31.89% |
| 2022 Q2 | 3.38 Million EUR | -34.42% |
| 2022 FY | 20.68 Million EUR | 48.28% |
| 2022 Q1 | 5.15 Million EUR | -5.5% |
| 2021 Q3 | 3.67 Million EUR | 37.29% |
| 2021 Q2 | 2.67 Million EUR | 51.78% |
| 2021 Q1 | 1.76 Million EUR | -15.63% |
| 2021 Q4 | 5.45 Million EUR | 48.29% |
| 2021 FY | 13.94 Million EUR | 62.45% |
| 2020 FY | 8.58 Million EUR | 150.03% |
| 2020 Q2 | 858 Thousand EUR | -18.44% |
| 2020 Q4 | 2.09 Million EUR | -49.78% |
| 2020 Q3 | 4.16 Million EUR | 385.55% |
| 2020 Q1 | 1.05 Million EUR | 24.64% |
| 2019 Q3 | 414 Thousand EUR | 0.0% |
| 2019 Q4 | 843.99 Thousand EUR | 103.86% |
| 2019 FY | 3.43 Million EUR | -33.0% |
| 2018 FY | 5.12 Million EUR | 32.22% |
| 2017 FY | 3.87 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 73.529% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 96.415% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 96.415% |
| Arcoma AB | 53.25 Million SEK | 58.817% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -341.356% |
| BICO Group AB (publ) | 2.84 Billion SEK | 99.23% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 89.579% |
| CellaVision AB (publ) | 295.99 Million SEK | 92.591% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | 68.184% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -1575.167% |
| C-Rad AB (publ) | 3.8 Million SEK | -477.132% |
| Duearity AB (publ) | 21.58 Million SEK | -1.603% |
| Dignitana AB (publ) | 74.73 Million SEK | 70.655% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -712.259% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.796% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -20.311% |
| Iconovo AB (publ) | 63.35 Million SEK | 65.384% |
| Integrum AB (publ) | 90.57 Million SEK | 75.786% |
| Luxbright AB (publ) | 23.09 Million SEK | 5.022% |
| Mentice AB (publ) | 237.06 Million SEK | 90.749% |
| OssDsign AB (publ) | 175.6 Million SEK | 87.511% |
| Paxman AB (publ) | 133.8 Million SEK | 83.609% |
| Promimic AB (publ) | 48.55 Million SEK | 54.83% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 86.494% |
| SciBase Holding AB (publ) | 69.97 Million SEK | 68.659% |
| ScandiDos AB (publ) | 61.03 Million SEK | 64.07% |
| Sectra AB (publ) | 39.06 Million SEK | 43.857% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 87.434% |
| Senzime AB (publ) | 141.51 Million SEK | 84.503% |
| SpectraCure AB (publ) | 12.12 Million SEK | -80.829% |
| Stille AB | 87.21 Million SEK | 74.855% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 99.606% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 95.026% |